13F filing recap · Q4 2010

What did ValueAct Capital buy in Q4 2010?

Reported stock-position changes between this filing and the previous one.

Stock value

$3.86B

Positions

Estimated turnover

51.1%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

New positions

VRXValeant Pharmaceuticals International, Inc.$762.70Mreported value+26.96M shares MCOMoody’s Corporation$162.24Mreported value+6.11M shares NYTThe New York Times Company$68.60Mreported value+7.00M shares

Increased positions

BCRC.r. Bard, Inc.$423.16Mreported value+364.3K shares+8.6%

Reduced positions

VRSNVeriSign Inc/ca$366.95Mreported value-600.0K shares-5.1%SNASnap-On Inc$232.08Mreported value-523.6K shares-11.3%ALRAlere Inc$181.55Mreported value-267.8K shares-5.1%

Exited positions

VRXValeant Pharmaceuticals International, Inc.$675.35Mprior reported value-26.96M shares-100.0%VRSKVerisk Analytics, Inc.$28.01Mprior reported value-1.00M shares-100.0%PLCMPolycom Inc$17.73Mprior reported value-650.0K shares-100.0%ALR 3 PERP BAlere Inc$10.78Mprior reported value